Tempus to Report Third Quarter 2024 Financial Results on November 4

TEM 11.04.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-04
Name of Upcoming Event:Earnings Conference Call
Full Press ReleaseSEC FilingsOur TEM Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Characterization of the Tumor Immune Microenvironment (TIME) and Somatic Landscape in Gastrointestinal (GI) Malignancies With MTAP Deletions (Del)
  • 01.21.2025 - Concordance Between Human Epidermal Growth Factor Receptor 2 (HER2) Status by Immunohistochemistry (IHC) and Next-Generation Sequencing (NGS) in Tissue and Blood Samples From Gastric and Gastroesophageal Junction Cancers (GC/GEJC)
  • 01.21.2025 - Association Between Ex Vivo Pharmacotyping of Patient-Derived Tumor Organoids and Personalized Therapeutic Options for Patients With Biliary Tract Cancer

Recent Filings

  • 01.22.2025 - 4/A Statement of changes in beneficial ownership of securities
  • 01.22.2025 - 144 Report of proposed sale of securities

CHICAGO--(BUSINESS WIRE)--Nov. 3, 2024--Tempus AI, Inc.(NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter onMonday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at4:30 p.m. ET. The company’s quarterly earnings will be released the same day. The company's conference call that was previously scheduled forNovember 7, 2024has been canceled.

The call will feature Tempus Founder and CEO,Eric Lefkofsky, and Chief Financial Officer,Jim Rogers. The live audio webcast will be accessible through theevents pageof Tempus’ Investor Relations website. Alternatively, the call can be accessed via the following:

Conference ID: 7177136Domestic Dial-in Number: (800) 715-9871International Dial-in Number: (646) 307-1963Live Webcast:https://edge.media-server.com/mmc/p/btq3mpjc

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visittempus.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241103229445/en/

Tempus CommunicationsErin CarronErin.carron@tempus.com

Tempus Investor RelationsElizabeth KrutoholowElizabeth.krutoholow@tempus.com

Source:Tempus AI, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com